StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Hydrochloric Acid → (1-{6-[5-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

HRID 71872
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 71872
Cl.C(OC([N:9]1[CH:14]([C:15]2[NH:19][C:18]3[CH:20]=[C:21]([C:24]4[CH:29]=[CH:28][C:27]([C:30]5[CH:35]=[CH:34][C:33]([C:36]6[NH:37][C:38]([CH:41]7[CH2:47][C:44]8([CH2:46][CH2:45]8)[CH2:43][N:42]7[C:48](OC(C)(C)C)=[O:49])=[N:39][CH:40]=6)=[CH:32][CH:31]=5)=[CH:26][CH:25]=4)[CH:22]=[CH:23][C:17]=3[N:16]=2)[CH:13]2[CH2:55][CH:10]1[CH2:11][CH2:12]2)=O)(C)(C)C.[CH3:56][O:57][C:58]([NH:60][CH:61]([CH:65]([CH3:67])[CH3:66])[C:62]([OH:64])=O)=[O:59].[CH3:68]N1CCOCC1.CN(C(ON1N=NC2[CH:86]=[CH:87][CH:88]=[N:89]C1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[C:99]([O:102][CH2:103]C)(=[O:101])C>O1CCOCC1.C(Cl)Cl>[CH3:103][O:102][C:99](=[O:101])[NH:89][CH:88]([C:48]([N:42]1[CH:41]([C:38]2[NH:37][C:36]([C:33]3[CH:32]=[CH:31][C:30]([C:27]4[CH:26]=[CH:25][C:24]([C:21]5[CH:22]=[CH:23][C:17]6[N:16]=[C:15]([CH:14]7[CH:12]8[CH2:11][CH:10]([CH2:55][CH2:13]8)[N:9]7[C:62](=[O:64])[CH:61]([NH:60][C:58]([O:57][CH3:56])=[O:59])[CH:65]([CH3:67])[CH3:66])[NH:19][C:18]=6[CH:20]=5)=[CH:29][CH:28]=4)=[CH:35][CH:34]=3)=[CH:40][N:39]=2)[CH2:47][C:44]2([CH2:45][CH2:46]2)[CH2:43]1)=[O:49])[CH:87]([CH3:68])[CH3:86]
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

9

Edukt 6

HCID 313Hydrochloric AcidHCID 79724-MethylmorpholineHCID 8857Ethyl AcetateHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 138211012-((Methoxycarbonyl)amino)-3-methylbutanoic acid
HCID 66620478
3-(6-{4'-[2-(5-tert-Butoxycarbonyl-5-aza-spiro[2.4]hept-6-yl)-3H-imidazol-4-yl]-biphenyl-4-yl}-1H-benzoimidazol-2-yl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester

Produkt 1

HCID 66620373(1-{6-[5-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl esterAusbeute 53 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 6344DichloromethaneLösungsmittelHCID 312751,4-DioxaneLösungsmittel

Versuchsvorschrift

4N HCl in dioxane (2 mL) was added to 3-(6-{4′-[2-(5-tert-Butoxycarbonyl-5-aza-spiro[2.4]hept-6-yl)-3H-imidazol-4-yl]-biphenyl-4-yl}-1H-benzoimidazol-2-yl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (53 mg, 0.073 mmol) in 2 mL DCM and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and dried overnight under vacuum. The residue was dissolved in DMF (1 mL) and to this solution was added 2-Methoxycarbonylamino-3-methyl-butyric acid (2.1 eq., 26.6 mg), 4-methylmorpholine (6 eq., 0.048 mL), followed by HATU (2 eq., 56 mg). Reaction mixture was stirred at 0° C. for 50 minutes. The reaction mixture was dissolved in ethyl acetate and washed with dilute sodium bicarbonate solution. The organic layer was dried (MgSO4), concentrated and purified by preparative reverse phase HPLC (GEMINI, 5 to 100% ACN/H2O+0.1% TFA). Product was lyophilized to give (1-{6-[5-(4′-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Example DH) (41.6 mg, 53%).

Aufarbeitung

  1. concentrationThe reaction mixture was concentrated
  2. customdried overnight under vacuum
  3. dissolutionThe residue was dissolved in DMF (1 mL) and to this solution
  4. customReaction mixture
  5. stirringwas stirred at 0° C. for 50 minutes
  6. washwashed with dilute sodium bicarbonate solution
  7. dry with materialThe organic layer was dried (MgSO4)
  8. concentrationconcentrated
  9. custompurified by preparative reverse phase HPLC (GEMINI, 5 to 100% ACN/H2O+0.1% TFA)

Quellen und Nachweise

ORD-Eintrag
ord-8d6d3091dfb04002b390793fe2555e35
Quelldatensatz
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US08822430B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion